ArticleNature communications2021
Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06939556 (Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Literature Review on the Use of Dried Biofluid Microsampling in Patients With Kidney Disease.Journal of clinical laboratory analysis · 2024Pooled it
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Evaluation of independent self-collected blood specimens for COVID-19 antibody detection among the US veteran population.Diagnostic microbiology and infectious disease · 2022Trial
- S375F mutation in Omicron variants causes destabilization and low production yield of SARS-CoV-2 recombinant Spike proteins.Protein expression and purification · 2026Article
- Point-of-care Diagnostic Framework for Fibromyalgia Using Integrated Vibrational Spectroscopy and Metabolomics.Research square · 2026Article
- Dual-mode aptamer-driven biosensing platform for ultrasensitive and mutation-resilient detection of the SARS-CoV-2 nucleocapsid protein.Genes & diseases · 2026Article
- The effect of personality on likelihood of contracting SARS-CoV-2 in the United States.Personality and individual differences · 2026Article
- Occlusion body-incorporated SARS-CoV-2 S-RBD via cypovirus polyhedrin-derived peptide: a novel insect cell-expressed antigen for high-accuracy COVID-19 diagnosis, and humoral immune response and hybrid immunity evaluation.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- 3D necroprinting: Leveraging biotic material as the nozzle for 3D printing.Science advances · 2025Article
- Magnetic Platinum-Cobalt Nanoparticles as Peroxidase Mimics for Detection of Cancer Biomarkers.ACS applied materials & interfaces · 2025Article
- Proteomic Profiling of Human Peripheral Blood Cell Targets of IgG Induced by SARS-CoV-2: Insights into Vaccine Safety.Vaccines · 2025Article
- Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen.International journal of molecular sciences · 2025Article
- Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States.The Journal of infectious diseases · 2025Article
- A modular cell-free protein biosensor platform using split T7 RNA polymerase.Science advances · 2025Article
- Molecular Biomarkers for Timely and Personalized Prediction of Maternal-Fetal Health Risk.Biomolecules · 2025Review
- Open-set deep learning-enabled single-cell Raman spectroscopy for rapid identification of airborne pathogens in real-world environments.Science advances · 2025Article
- Humoral Immunity Profiling to Pandemic and Bat-Derived Coronavirus Variants: A Geographical Comparison.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.BMJ public health · 2025Article
- Performance and feasibility of self-microsampling of capillary blood and saliva for serological testing of SARS-CoV-2.PloS one · 2025Article
- Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants.Biotechnology letters · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
21 authors.
Funding
Abstract
The extent of SARS-CoV-2 infection throughout the United States population is currently unknown. High quality serology is key to avoiding medically costly diagnostic errors, as well as to assuring properly informed public health decisions. Here, we present an optimized ELISA-based serology protocol, from antigen production to data analyses, that helps define thresholds for IgG and IgM seropositivity with high specificities. Validation of this protocol is performed using traditionally collected serum as well as dried blood on mail-in blood sampling kits. Archival (pre-2019) samples are used as negative controls, and convalescent, PCR-diagnosed COVID-19 patient samples serve as positive controls. Using this protocol, minimal cross-reactivity is observed for the spike proteins of MERS, SARS1, OC43 and HKU1 viruses, and no cross reactivity is observed with anti-influenza A H1N1 HAI. Our protocol may thus help provide standardized, population-based data on the extent of SARS-CoV-2 seropositivity, immunity and infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.